Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. 2017

Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.

Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.

UI MeSH Term Description Entries
D008495 Medical Oncology A subspecialty of internal medicine concerned with the study of neoplasms. Oncology, Medical,Clinical Oncology,Oncology, Clinical
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016903 Drug Monitoring The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically. Monitoring, Drug,Therapeutic Drug Monitoring,Drug Monitoring, Therapeutic,Monitoring, Therapeutic Drug
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
October 2023, Clinical pharmacokinetics,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
September 2020, Clinical pharmacology and therapeutics,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
March 2019, Clinical pharmacology and therapeutics,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
January 2006, Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
August 2016, Oncology letters,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
April 2014, Clinical pharmacokinetics,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
June 1988, Drugs,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
January 2017, Clinical pharmacology : advances and applications,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
February 2012, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico,
Remy B Verheijen, and Huixin Yu, and Jan H M Schellens, and Jos H Beijnen, and Neeltje Steeghs, and Alwin D R Huitema
October 2013, Therapeutic drug monitoring,
Copied contents to your clipboard!